31results about How to "Inhibition of degranulation" patented technology

The invention discloses a method for preparing atomized liquid for treating infantile asthmatic suffocating pneumonia. The atomized liquid comprises gleditsia fruit, loquat leaf, European hop flower, Chinese waxgourd semen, common bluebeard herb, platycodon root, red clover, whiteflower hogfennel root and borneol which serve as raw materials. The method is characterized by comprising the following steps of: (1) extracting the loquat leaf, the European hop flower and the common bluebeard herb by a supercritical fluid extraction method to obtain volatile oil; (2) crushing the gleditsia fruit and the borneol into superfine powder; (3) decocting the red clover, the whiteflower hogfennel root, the Chinese waxgourd semen and the platycodon root in water twice, filtering, mixing filtrates, and concentrating at the temperature of 80 DEG C until the relative density is 1.1 to obtain a water extracting solution; and (4) stirring the volatile oil obtained in the step (1), the superfine powder obtained in the step (2) and the water extracting solution obtained in the step (3) uniformly, standing at normal temperature for 12 hours, and filtering to obtain liquid medicine. Clinical experiments prove that the atomized liquid prepared by the method has an obvious treatment effect, and the hospital stays can be shortened.

The invention belongs to the technical field of biotechnology and relates to a human IgE (immunoglobulin E) Fab (fragment ab) against human and a coding gene and application thereof. In the invention, a recombined IgE C3-C4 protein is used for screening a natural human immunoglobulin gene library, and a human antibody Fab of IgE against human is screened from the library through ELISA (enzyme-linked immunosorbent assay) sequencing analysis and the like; extensive expression purification and further identification prove that the antibody Fab of human IgE against human is fully human and without Fc (fragment c), has an effect of inhibiting IgE mediated anaphylaxis without activating complements or causing human immune response or other pathological lesions and can be used for preparing antibody drugs for treating allergic diseases caused by IgE.

The invention discloses bifidobacterium longum NX-4 and application thereof in preparation of drugs for treating and/or preventing allergic diseases, and belongs to the technical field of microorganisms. The invention discloses a bifidobacterium longum NX-4 strain, and the preservation number is CGMCC No. 20112. Bifidobacterium longum NX4 inactivated and non-inactivated fermentation supernatant and bacterial suspension can obviously inhibit Compoud 48/80 from stimulating zebra fish to secrete Tryptase in vivo, and have the potential of being applied to relieving or preventing anaphylactic reaction in vivo. The bifidobacterium longum NX-4 disclosed by the invention has a huge potential application prospect in the aspect of relieving and/or preventing allergic reaction.

The invention discloses a medicinal composition for treating child asthmatic suffocating pneumonia. The medicinal composition is characterized by being processed from multiple Chinese medicines in parts by weight: 1-3 parts of Chinese honey locust, 6-9 parts of loguat leaf, 10-15 parts of european hop flower, 10-15 parts of waxgourd seed, 6-9 parts of common bluebeard herb, 6-9 parts of platycodon root, 10-15 parts of red clover flower and inflorescence, 6-9 parts of whiteflower hogfennel root and 1-3 parts of borneol. As proved by clinical experiments, the medicinal composition for treating child asthmatic suffocating pneumonia has the characteristics of good curative effect and high safety, and is worthy of clinical application and popularization.

The invention discloses novel application of dictamnine, in particular to application of the dictamnine in preparing type I hypersensitivity reaction drugs caused by mast cell activation, and belongsto the field of pharmaceuticals. According to the dictamnine disclosed by the invention, by constructing a C48/80 induced P815 mast cell in vitro inflammatory model, the dictamnine is found to have the effects of inhibiting the activation of mast cells, effectively inhibiting the degranulation degree of the mast cells in a sensitized state and alleviating the release of beta-hexosaminidase; the expression of inflammatory genes IL-4, IL-6, IL-12 and IL-13 in the mRNA level can be inhibited; in addition, the phosphorylation level of ERK in an intracellular signaling pathway can be significantlyinhibited.

The invention discloses a traditional-Chinese-medicine active compound with the Syk inhibitory activity and its preparation method and application. It is found that the active compound, namely ginkgolic acid C15:1 or ginkgolic acid C13:0, has the spleen tyrosine kinase (Syk) inhibition activity, research further shows that the active compound has the effect of inhibiting mastocyte degranulation, the traditional-Chinese-medicine active compound ginkgolic acid C15:1 is obtained from ginkgo medicinal materials for the first time, and it is verified that the traditional-Chinese-medicine active compound ginkgolic acid C15:1 has the Syk inhibition activity and the mastocyte degranulation inhibition activity. The effective component and chemical component of the active compound ginkgolic acid C15:1 or ginkgolic acid C13:0 are simple, the action target is clear, the Syk activity can be directly inhibited, the mastocyte degranulation is inhibited, the action mechanism of the ginkgolic acid C15:1 or ginkgolic acid C13:0 is easier to illuminate in pharmacological research, and the ginkgolic acid has a potential application value in the prevention and treatment of allergic asthma and provides a new medicine selection for the prevention and treatment of allergic asthma.

The invention discloses a preparation method of an itching relieving cream for treating seborrheic dermatitis, and belongs to the field of medicines. According to the preparation method, through extracting a main active component-alkaloid from semen sophorae alopecuroidis, a drug, which has a stabilizing effect on an erythrocyte membrane, of the alkaloid has the stabilizing effect on a lysosome membrane; thus, the release of an inflammatory mediator is reduced; an anti-inflammatory purpose is achieved; meanwhile, the alkaloid also has an antiallergic effect, can be used for suppressing the degranulation of a mast cell, and has favorable effects on balancing grease secretion, relieving pruritus, resisting imflammation and resisting an allergy and immunologic suppression; thus, the use effect of the itching relieving cream is improved; the alkaloid is mixed with distillate prepared from glucose and ethylene glycol; as having multiple hydroxyl groups, the alkaloid has quite high affinitywith water, has a moisturizing effect on skin, and thus, can be also used for retaining moisture for the skin while being used for removing grease on the surface of the skin; a problem that the skin is dry is avoided, and the itching relieving cream is used for solving problems that a current conventional itching relieving cream has poor transdermal absorption and an unconspicuous use effect.

The invention discloses lactobacillus gasseri LGV03 and application thereof, and belongs to the technical field of microorganisms. The preservation number of the lactobacillus gasseri LGV03 is CGMCC No.22010. A fermentation supernatant and a bacterial suspension of the lactobacillus gasseri LGV03 can remarkably inhibit the secretion of Trypase by the zebra fish stimulated by Compound 48/80 in vivo, can inhibit in-vivo mast cell degranulation, and have the potential of being applied to in-vivo anaphylactic reaction prevention. The lactobacillus gasseri LGV03 disclosed by the invention has a huge potential application prospect in the aspect of preventing anaphylactic reaction.

The invention discloses application of protocatechualdehyde in preparing a medicine for preventing and/or treating bronchial asthma. Specifically, when being applied to early asthma, the protocatechualdehyde not only can remarkably control airway inflammation of the asthma, but also has the effects on protecting vascular endothelial cells of the lung, inhibiting mast cell degranulation, inhibiting fibroblast from secrete collagen, promoting apoptosis and calming by improving blood circulation in lung of asthma, reducing blood viscosity and improving anoxic state of the asthma, so as to relieve or inhibit airway remodeling from various aspects and various links; and inhibiting morphological change of the airway remodeling, effect of the medicine is better than prednisone acetate, and the medicine is free from side effect.

The invention discloses application of limonene in preparation of an anti-allergic dermatitis drug, and belongs to the technical field of biological medicines. The limonene can inhibit DNCB acetone solution induced contact dermatitis, and has the effects of inhibiting passive skin allergic reaction and mast cell degranulation; therefore, the limonene can be used for treating allergic dermatitis caused by various reasons, and has a better treatment effect.

The invention discloses new application of paeoniflorin, particularly relates to application of the paeoniflorin to preparation of a medicine for treating I type hypersensitivity reaction caused by hypertrophy cell activation, and belongs to the field of medicine. Through construction of a C48/80 induced P815 hypertrophy cell extracellular inflammation model, the invention discovers that the paeoniflorin has the effect of inhibiting hypertrophy cell activation, can effectively inhibit the degranular degree of the hypertrophy cells under the sensitization state and relieve release of beta-aminophenin, can inhibit expression of inflammatory genes IL-4, IL-6, IL-12 and IL-13 and expression of key receptors PAR2, PAR3 and PAR4 in a hypertrophy cell activation path on the mRNA level, and can obviously limit the phosphorylation level of ERK in an intracellular signal path.

The invention provides a soothing anti-allergy nano-vesicle composition and application thereof. The soothing anti-allergy nano-vesicle composition is prepared from the following components in percentage by mass: 1-10% of a magnolia flower extract; 0.5-5% of a rosemary extract; 1-10% of an olive leaf extract; 30-60% of an emulsifier; 10-30% of a humectant; and 10-30% of an emulsion stabilizer. The soothing and anti-allergy nano-vesicle composition disclosed by the invention contains water-soluble and oil-soluble active ingredients at the same time, has the effects of quickly soothing and resisting allergy, and has the effects of repairing, conditioning and maintaining the stability of skin for a long time. The soothing and anti-allergy nano-vesicle composition can be used for a conventional emulsification system and a transparent aqueous system, the preparation method is simple and controllable, the repeatability is good, the effect is obvious, and the soothing and anti-allergy nano-vesicle composition can be applied to various cosmetics with anti-allergy and soothing effects.

The invention relates to an application of notoginsenoside for treating septicemia, particularly relates to ginsenoside Rb1 which is the effective component of notoginsenoside, and an application of ginsenoside Rb1 and notoginsenoside R1 in treating and/or preventing septicemia.

The invention relates to novel application of a Chaenomeles speciosa (sweet) Nakai extract, specifically to application of oleanolic acid, ursolic acid, oleanolic saponins and ursolic saponins in the extract in the pharmaceutical field. The extract has effects on inhibition of DNP-BSA induced RBL-2H3 mast cell degranulation, DNP-BSA induced mBMMCs mast cell degranulation, calcium ionophore A23187 induced RBL-2H3 mast cell degranulation and Thapsigargin induced RBL-2H3 mast cell degranulation and on xylene-induced acute inflammation like ear swelling of mice and has a high medicinal value.

The invention discloses an application of a compound in preparation of anti-allergic drugs, and is characterized in that the molecular formula of the compound is C29H27NO8, and the chemical structural formula of the compound is shown in the specification. The study finds that the compound T-5224 can obviously inhibit release of beta-aminoglycosidase in mast cells, has an obvious effect of inhibiting degranulation of the mast cells, and can obviously inhibit the allergic reaction in mice. Therefore, the T-5224 compound can be used for preparing the anti-allergic drugs and has a wide application prospect.